Actively Recruiting
The Effects of the CF Carrier State on the Kidneys and Pancreas
Led by Philip Polgreen · Updated on 2026-01-07
1250
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
P
Philip Polgreen
Lead Sponsor
N
National Institutes of Health (NIH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying whether carriers of the Cystic Fibrosis (CF) gene have a higher risk of developing certain pancreatic and kidney problems compared to people without the gene. This observational study aims to detect early signs of these disorders by comparing CF carriers and controls. The study is led by Philip Polgreen and involves one clinic visit and optional at-home sample collections. During the clinic visit, all participants will have measurements taken for height, weight, and blood pressure. They will undergo a 2-hour oral glucose tolerance test (OGTT) with several blood draws before, during, and after the test to measure glucose, insulin, and other related blood markers. Participants will also complete surveys about their health and medications. A smaller group of volunteers may collect urine and stool samples at home and return them for lab testing. Participants will be involved in one clinic visit lasting about 3 to 4 hours, during which they will complete surveys and provide blood samples. Volunteers collecting urine and stool samples will follow instructions at home and return the samples later. Researchers will compare glucose and insulin levels as primary outcomes, along with other markers like C-reactive protein, lactoferrin, calprotectin, and lipid values. The study will monitor these results to better understand the health risks for CF carriers.
CONDITIONS
Brief Title
The Effects of the CF Carrier State on the Kidneys and Pancreas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 100 years
- CF Carriers identified via genetic testing
- Controls with no previous CF carrier test results
- Able to speak English
- Able to provide written informed consent
You will not qualify if you...
- Diagnosed with cystic fibrosis
- Currently pregnant
- Prisoner status
- Currently taking medications for diabetes treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 to 4 hours
Participants attend a clinic visit where height, weight, and blood pressure are measured. They undergo a 2-hour oral glucose tolerance test (OGTT) with multiple blood draws and complete a baseline survey and medication interview during the visit.
1 visit (in-person)
Duration - Variable based on sample collection timing
Volunteers in a subsample collect 24-hour urine and/or stool samples at home following detailed instructions and return them to the research team at a scheduled date and time.
1 to 2 visits depending on sample return
Trial Site Locations
Total: 1 location
1
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States, 52242
Actively Recruiting
Research Team
P
Philip M Polgreen, MD
S
Shelby L Francis, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here